ICU Medical's 15min chart shows KDJ Death Cross, Bearish Marubozu pattern.

ICU Medical's 15-minute chart has exhibited a significant technical indicator, the KDJ Death Cross, which was triggered along with a Bearish Marubozu at 08/20/2025 10:30. This suggests that the momentum of the stock price is shifting towards a downward trend, with potential for further decreases. The dominance of sellers in the market and the likelihood of bearish momentum persisting underscores the importance of closely monitoring the stock's performance in the coming days.

ICU Medical Inc. (NASDAQ: ICUI) experienced a significant shift in its stock price momentum on August 20, 2025, at 10:30, as the 15-minute chart triggered a KDJ Death Cross and a Bearish Marubozu. These technical indicators suggest a shift in market sentiment towards the downside, potentially leading to further decreases in the stock's value.

The KDJ Death Cross occurs when the KDJ line crosses below the signal line, indicating a change in momentum from bullish to bearish. The appearance of a Bearish Marubozu candlestick pattern further supports this bearish sentiment. A Marubozu candlestick is characterized by a long body without any upper or lower wicks, suggesting strong buying or selling pressure with no reversal.

ICU Medical reported its second quarter 2025 financial results, with earnings per share (EPS) of $2.10, exceeding analyst expectations by $0.60 per share. The company's revenue fell by 6.4% to $543.57 million, slightly missing the expected $542.50 million. Despite the revenue decline, the company reported a net income of $35.34 million for the quarter.

The company's stock price has been volatile, falling by 4.0% this quarter and losing 18.2% so far this year. The stock closed at $129.91 on the day of the presentation, up 2.38%.

The joint venture (JV) with Otsuka Pharmaceutical, Factory America, Inc., has significantly impacted ICU Medical's financial profile. The JV transaction led to a 6% year-over-year revenue decline, primarily driven by the transfer of the IV Solutions business. The company's Vital Care segment, which previously included the IV Solutions business, experienced a 34% year-over-year decline.

ICU Medical's adjusted EBITDA for Q2 2025 was $100.3 million, beating analyst estimates by 18.3%. The company's adjusted EPS for the quarter was $1.43, significantly above analysts' consensus estimates of -$0.47. The company's full-year EPS guidance at the midpoint of $7 per share is a 443% beat over analyst estimates.

Looking ahead, ICU Medical expects gross margin to improve to 39-40% for the full year, with further improvement to 40-41% in the second half of 2025. The company's operating expenses are projected at approximately 25% of revenue for the full year, increasing to about 26% in the second half. Capital expenditures have been revised downward to $75-95 million, reflecting a reduction of approximately $15 million due to the JV.

Investors should closely monitor ICU Medical's performance as it navigates this transition period and whether the projected margin improvements materialize as expected in the coming quarters.

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U00KO:0-icu-medical-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[2] https://uk.investing.com/news/company-news/icu-medical-q2-2025-slides-jv-impact-drives-revenue-decline-guidance-adjusted-93CH-4209246
[3] https://finance.yahoo.com/news/icu-medical-nasdaq-icui-q2-083330019.html